New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
08:39 EDTCPXXCelator Pharmaceuticals initiates PK/PD clinical study of CPX-351
Celator Pharmaceuticals announced that the first patient has been enrolled in a Phase 2 pharmacokinetic and pharmacodynamics, or PK/PD, study evaluating the effects of CPX-351 Liposome Injection on cardiac repolarization in adult patients with acute hematologic malignancies, including acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, and myelodysplastic syndrome, or MDS. This study will also include patients with moderate baseline hepatic and renal impairment, extending the range of safety and pharmacokinetic observations to this important group of patients.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
08:18 EDTCPXXCelator Pharmaceuticals presents positive data for its CPX-351 candidate
Celator Pharmaceuticals presented data for CPX-351, its lead product candidate, describing the effects of combining CPX-351 with traditional chemotherapy and novel molecularly targeted agents intended for use in treating AML and other blood cancers. In both cases, the combined agents complemented each other's anti-leukemic properties, resulting in an enhanced overall effect. Chk1 inhibitors and CPX-351 synergized to induce increased DNA fragmentation and apoptosis, leading to increased leukemia cell kill in a number of AML lines as well as in AML patient blasts.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use